Trials / Completed
CompletedNCT01810770
Radium-223 Dichloride Asian Population Study in the Treatment of CRPC Patients With Bone Metastasis
A Single-arm, International, Prospective, Interventional, Open-label, Multicenter Study of Radium-223 Dichloride in the Treatment of Patients With Castration-Resistant Prostate Cancer (CRPC) With Bone Metastasis.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 243 (actual)
- Sponsor
- Bayer · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and efficacy (Overall survival \[OS\]) of multiple doses of Ra-223 dichloride in an Asian population of subjects with CRPC metastatic to the bone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Radium-223 dichloride (Xofigo, BAY88-8223) | Radium-223 dichloride, 55 kBq/kg body weight, will be administered as a slow bolus IV injection at 4 week intervals for up to 6 doses. |
Timeline
- Start date
- 2013-03-26
- Primary completion
- 2017-09-25
- Completion
- 2017-09-25
- First posted
- 2013-03-14
- Last updated
- 2018-09-19
Locations
27 sites across 4 countries: China, Singapore, South Korea, Taiwan
Source: ClinicalTrials.gov record NCT01810770. Inclusion in this directory is not an endorsement.